Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

NCT04112303 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: SOF/VEL

Sponsor

Gilead Sciences